Opal Capital LLC Invests $4.45 Million in Roche Holding AG $RHHBY

Opal Capital LLC bought a new position in shares of Roche Holding AG (OTCMKTS:RHHBY) in the first quarter, HoldingsChannel reports. The firm bought 89,483 shares of the company’s stock, valued at approximately $4,448,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Oakworth Capital Inc. increased its holdings in Roche by 20.8% in the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock valued at $86,000 after acquiring an additional 285 shares during the last quarter. Enterprise Financial Services Corp boosted its holdings in shares of Roche by 6.6% during the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after purchasing an additional 345 shares during the last quarter. Archer Investment Corp grew its position in shares of Roche by 7.7% during the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock valued at $278,000 after purchasing an additional 398 shares in the last quarter. Diversified Trust Co increased its holdings in shares of Roche by 0.8% in the first quarter. Diversified Trust Co now owns 59,375 shares of the company’s stock worth $2,907,000 after purchasing an additional 448 shares during the last quarter. Finally, Hancock Whitney Corp increased its holdings in shares of Roche by 4.8% in the third quarter. Hancock Whitney Corp now owns 24,488 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,116 shares during the last quarter.

Roche Price Performance

Roche stock opened at $56.52 on Wednesday. The company’s 50-day moving average price is $51.64 and its 200-day moving average price is $52.76. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche Holding AG has a twelve month low of $37.51 and a twelve month high of $60.85.

Analysts Set New Price Targets

A number of equities analysts recently commented on RHHBY shares. Argus raised Roche from a “hold” rating to a “buy” rating in a research note on Monday, April 6th. Zacks Research downgraded Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Morgan Stanley raised Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective on the stock in a report on Friday, April 24th. Finally, HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Roche currently has an average rating of “Hold” and an average price target of $51.50.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.